Abstract
Palivizumab is a humanized monoclonal antibody directed against the respiratory syncytial virus (RSV) F glycoprotein. It is delivered by monthly intramuscular injection during the RSV season. It is indicated for prematurely born infants up to gestational age 35 weeks and children with congenital heart disease to prevent hospital admission by RSV infection. Palivizumab has been shown to prevent recurrent wheeze in the first year of life in otherwise healthy preterm gestational age 33-35 weeks.
Original language | English |
---|---|
Title of host publication | Approved Therapeutic Antibodies and in vivo Diagnostics |
Publisher | Wiley-Blackwell |
Pages | 1825-1854 |
Number of pages | 30 |
Volume | 4-4 |
ISBN (Electronic) | 9783527682423 |
ISBN (Print) | 9783527329373 |
DOIs | |
Publication status | Published - 3 Dec 2014 |
Keywords
- Bronchiolitis
- Fusion
- Infants
- Non-human target
- Respiratory syncytial virus
- Wheeze